Thursday, February 15 2024, 4pm 204 Caldwell Hall Event Flyer (218.56 KB) Hiya Banerjee Biostatistician Eli Lilly The Impact Of Treatment Discontinuation Due Adverse Events On Efficacy In An Oncology Clinical Trial Abstract Randomized clinical trials persist as the gold standard for evaluating the efficacy and safety of new treatments. However, in clinical trials of reasonable size and duration, it is common for some patients to deviate from their assigned study treatment due to various reasons. One such deviation is treatment discontinuation resulting from adverse events. The lingering question revolves around how to estimate the impact of treatment discontinuation due to adverse events on the efficacy of a drug. Motivated by a health authority question, I will present how principal stratum analysis can help in addressing this question for an oncology clinical trial. Lunch Talk: 12:30pm Room 434, Cohen Room, Brooks Hall This presentation will explore the role of biostatisticians in the pharmaceutical industry. I will discuss what key skillsets and behaviors are generally required to have a successful career in this industry. This will be an informal conversation about possible career paths with time for interactions and questions About the Speaker Dr. Hiya Banerjee serves as the Director of Biostatistics at Eli Lilly and Company, where she assumes a pivotal role in shaping the statistical approaches and methodologies used in clinical drug development, emphasizing the utmost rigor and precision. Dr Banerjee's expertise extends across various therapeutic areas, including Oncology and Diabetes, where her contributions to clinical research have led to significant advancements in patient care and treatment. Her professional interests encompass survival analysis, multiple imputation techniques, causal inference, and their practical application in the context of drug development. Dr Banerjee has actively participated in a diverse array of initiatives within both the International Indian Statistical Association (IISA) and the American Statistical Association Biopharmaceutical Section (ASA-BIOP). Dr. Banerjee has been elected as the president-elect for IISA. Additionally, she holds various positions within ASA-BIOP. Her engagement in these organizations is driven by her fervent desire to inspire and empower young professionals, helping them uncover their purpose and unlock their full potential. Dr. Banerjee earned her PhD in Applied Statistics from the University of California, Riverside, and holds Master’s and Bachelor’s degrees in Statistics from the University of Calcutta. Additionally, she holds an Masters in Business Administration (MBA) from Rutgers University.
